Lactoferrin Inhibits Hepatitis C Virus Viremia in Patients with Chronic Hepatitis C: A Pilot Study
Katsuaki Tanaka, 1, 4 Masanori Ikeda, 1, 2 Akito Nozaki, 1, 2 Nobuyuki Kato, 2 Hiroyuki Tsuda, 3 Satoru Saito 1 Hisahiko Sekihara 1
1 Third Department of Internal Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 2 Virology Division, National Cancer Center Research Institute, Tokyo 104-0045 3 Experimental Pathology and Chemotherapy Division, National Cancer Center Research Institute, Tokyo 104-0045
4 To whom correspondence should be addressed. E-mail: tanaka97@med.yokohama-cu.ac.jp
Copyright Japanese Cancer Association 1999
KEYWORDS
Lactoferrin • Chronic hepatitis • Hepatitis C virus
ABSTRACT
Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.
Received November 13, 1998/Revised March 11, 1999/Accepted March 16, 1999
DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1349-7006.1999.tb00756.x
Katsuaki Tanaka, 1, 4 Masanori Ikeda, 1, 2 Akito Nozaki, 1, 2 Nobuyuki Kato, 2 Hiroyuki Tsuda, 3 Satoru Saito 1 Hisahiko Sekihara 1
1 Third Department of Internal Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 2 Virology Division, National Cancer Center Research Institute, Tokyo 104-0045 3 Experimental Pathology and Chemotherapy Division, National Cancer Center Research Institute, Tokyo 104-0045
4 To whom correspondence should be addressed. E-mail: tanaka97@med.yokohama-cu.ac.jp
Copyright Japanese Cancer Association 1999
KEYWORDS
Lactoferrin • Chronic hepatitis • Hepatitis C virus
ABSTRACT
Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.
Received November 13, 1998/Revised March 11, 1999/Accepted March 16, 1999
DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1349-7006.1999.tb00756.x
Hiç yorum yok:
Yorum Gönder